PERSONAL DETAIL


PROF. DR. ANITA ZARINA BINTI BUSTAM @ MAINUDIN

Faculty of Medicine Dean's Office
Faculty of Medicine
 
  +603-79492185
  +603-79563072
  anitabustam@um.edu.my
 Faculty of Medicine Dean's Office, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, W.Persekutuan Kuala Lumpur, Malaysia
 
ResearcherID Link
  http://www.researcherid.com/rid/B-8233-2010


BIBLIOMETRIC DATA


 Total Articles in Publication List  23
 Articles With Citation Data  20
 Sum of the Times Cited   267
 Average Citations per Article   13.35
 h-index   9
 Co-authors   Collaboration Network
 This information is generated from http://researcherid.com

ACADEMIC QUALIFICATION
(Qualification), (Institution).



PROFESSIONAL
(Organisation), (Role), (Year), (Level).


  • Royal College of Radiologists, London, Member, 1995, (International)
  • Malaysian Oncological Society, Life Member, 2000, (National)
  • Malaysian Oncological Society, Committee, 2001, (National)
  • Asia Pacific Hospice Network, Member, 2003 to 2007, (International)
  • Academy of Medicine Malaysia, Member, 2009, (National)
  • SEAROG, Committee Member, 2011 to 2013, (International)
  • NPC Society of Malaysia, Exco Member, 2011 to 2013, (National)
  • NPC society of Malaysia, Life Membership, 2011, (National)
  • SEAROG, Exco Member, 2014, (International)
  • FARO, Elected Council Member, 2014, (International)
  • ESTRO, Membership, 2016 to 2016, (International)

ADMINISTRATIVE DUTIES
(Role), (Level), (Start date),(End Date).


  • Head, Clinical Oncology Unit, Faculty of Medicine, 01/09/2012 to 31/08/2013
  • National Project Coordinator, International, 30/01/2018 to 31/12/2021 (RAS 6086 project Strengthening cancer management programmes in RCA states parties through collaboration with national and regional radiation oncology societies)
  • HRPP Committee member, Faculty, 02/05/2017 to 01/05/2019
  • JKKF Committee member, University Malaya, 06/04/2017 to 05/04/2020 (JKKF)
  • Programme Coordinator, University Malaya, 02/09/2016 to 01/09/2017 (Programme Coordinator for Master of Clinical Oncology)
  • Quality Manager, University Malaya, 04/07/2016 to 03/07/2017 (DQM Clinical Oncology)
  • AJK Penulisan Kurikulum Nasional Sarjana Perubatan Klinikal bagi bidang Onkologi Klinikal, National, 01/01/2016
  • Postgraduate Curriculum Working Group, Faculty, 23/09/2014
  • Programme Coordinator, Faculty, 01/09/2014 to 01/09/2016
  • Quality Manager, Faculty, 01/07/2014 to 01/07/2016
  • Ahli Jawatankuasa PPGP, Faculty, 01/10/2013
  • National Project Coordinator for IAEA project RAS6040, National, 01/01/2005 to 31/12/2009
  • Head Coordinator, Faculty, 01/10/2002 to 31/08/2013 (Master of Clinical Oncology programme)
  • Head of Department, Faculty, 01/08/2000 to 31/08/2013 (Current appointment till end August 2013)

AREAS OF EXPERTISE
(Area).


  • Clinical Oncology Which Covers All Aspects of Non-Surgical Treatment Modalities for Cancer Patients in Particular With Radiotherapy, Cytotoxics, Hormones and Biologics. Tumour Site Specialization Includes Breast,Lung, Brain, Lymphoproliferative Tissue, Paediatrics and Skin.


RECENT SELECTED PUBLICATIONS
(Publication).


Article in Academic Journals

2019
  • Survival of oral cancer patients in different ethnicity (ISI-Indexed)
  • Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early-stage HER2-positive breast cancer (ISI-Indexed)

2018
  • Syadwa Abdul Shukor, Anita Zarina Bustam, Palliative radiotherapy for advanced Cancer: Are we giving it to the right patient at the right time?Med J Malaysia Vol 73 No 4 August 2018 (SCOPUS-Indexed)

2017
  • Moradi, F., Ung, N.M., Khandaker, M.U., Mahdiraji, G.A., SAAD, M., Malik, R.A., Bustam, A.Z., Zaili, Z. and Bradley, D.A.,(2017). Monte Carlo skin dose simulation in intraoperative radiotherapy of breast cancer using spherical applicators. Physics in medicine and biology. 62, 6550-66. (ISI-Indexed)
  • Miguel Martin, MD et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology Nov 13, 2017 (ISI-Indexed)
  • Rosenblatt, E.,Prajogi, G. B., Barton, M., Fidarova, E.,Eriksen, J. G., Haffty, B., Millar, B. A.,Bustam,A., Zubizarreta, E., & Abdel-Wahab,M. (2017). Need for Competency-Based Radiation Oncology Education in Developing Countries. Creative Education, 8, 66-80. (ISI-Indexed)

2016
  • The challenges of treating childhood medulloblastoma in a country with limited resources: 20 years experience at a single tertiary centre in Malaysia. Journal of Global Oncology, 2016 (Non-ISI/Non-SCOPUS)

2015
  • Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, MARNIZA SAAD, Adlinda Alip, Wan Zamaniah Wan Ishak. Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice (ISI-Indexed)
  • Yahaya NA1, Subramanian P, Bustam AZ, Taib NA.2015.Symptom Experiences and Coping Strategies among Multi- ethnic Solid Tumor Patients Undergoing Chemotherapy in Malaysia.Asian Pac J Cancer Prev 16(2):723-30. (ISI-Indexed)
  • Chandramathi S, Suresh K, Anita ZB, Rokiah P, Kuppusamy UR. Urinary Advanced Oxidation Protein Product (AOPP): A Potential Oxidation Damage Marker for Cancer . West Indian Medical Journal, In press. (ISI-Indexed)

2013
  • Zain RB, Athirajan V, Ghani WM, Razak IA, Raja Latifah RJ, Ismail SM, Sallam AA, Bustam AZ, Rahman ZA, Hussien A, Talib N, Cheong SC, Jallaludin A.2013 An oral cancer biobank initiative: a platform for multidisciplinary research in a developing country. Cell Tissue Bank. 14(1):45-52 (ISI-Indexed)
  • Nor Zuraida Zainal, Norley Shuib, Anita Zarina Bustam, Zuraida Ahmad Sabki, Ng Chong Guan. 2013. Reliability and Validity of the Malay Version of the Breast-Impact of Treatment Scale (MVBITS) in Breast Cancer Women undergoing Chemotherapy. Asian Pacific J Cancer Prev, 14 (1), 463-468 (ISI-Indexed)

2012
  • Chee Ee Phua, Anita Zarina Bustam, Mastura Md Yusof, MARNIZA SAAD, Cheng-Har Yip, Nor Aishah Taib and Char Hong Ng. 2012 Risk of treatment related death (TRD) with adjuvant chemotherapy for breast cancer: A study in University Malaya Medical Centre (UMMC). Journal of Cancer Therepeutics & Research 1: 13 (SCOPUS-Indexed)
  • Phua Chee Ee, Anita Zarina Bustam,Mastura Md Yusof, MARNIZA SAAD,Yip Cheng-Har, Nor Aishah Taib, Ng Char Hong, Teh Yew Ching 2012. Risk of Treatment Related Death and Febrile Neutropaenia with Taxane-Based Adjuvant Chemotherapy for Breast Cancer in a Middle Income Country Outside a Clinical Trial Setting. Asia Pacific Journal of Cancer Prevention; 13(9), 4623-4626. (ISI-Indexed)

2011
  • Chandramathi S,Suresh K,Anita ZB,Kuppusamy UR (2011). Infection of Blastocystis hominis and microsporidia: are they opportunistic? Trans. R. Soc. Trop. Med. Hyg. (ISI-Indexed)

2010
  • Prognostic Factors for Elderly Breast Cancer Patients in University Malaya Medical Centre, Malaysia CE Phua1*, AZ Bustam2, Cheng-Har Yip3, Nor Aishah Taib3 2010 Asian Pacific J Cancer Prev, 11, 1205-1211 (ISI-Indexed)
  • Hoong-Yin Chong, Nur Aishah Taib, Sanjay Rampal, Marniza Saad, Anita Zarina Bustam, Cheng-Har Yip. Treatment options for locally advanced breast cancer - experience in an Asian tertiary hospital. APJCP, 11:2010;1-5. (ISI-Indexed)
  • Shingo Kato, Tatsuya Ohno, Kullathorn Thephamongkol, Yaowalak Chansilpa, Yang Yuxing, C.R.Beena Devi, Anita Z. Bustam, Miriam J.C. Calaguas, Rey H. De Los Reyes, Chul-Koo Cho, To Anh Dung, Nana Supriana, Hideyuki Mizuno, Takashi Nakano, Hirohiko Tsujii. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia. Int J Radiation Oncology Biol Phys Vol 77 No 3 pg 751-757, 2010 (ISI-Indexed)
  • Lau Peng Choong, Nur Aishah Mohd Taib, Sanjay Rampal, Marniza Saad, Anita Zarina Bustam, Yip Cheng Har; High Tumour Stage and Margin Clearance are still important prognostic factors for post-mastectomy locoregional recurrence in Malaysia; Asian Pacific Journal for Cancer Prevention,11,1409-1416 Dec 2010 (ISI-Indexed)
  • Seriramalu R, Pang W, Jayapalan JJ, Mohamed E, Abdul- Rahman PS, Bustam AZ, Khoo ASB, Hashim OH;Application of champedak mannose-binding lectin in the glycoproteomic profiling of serum samples unmasked reduced expression of alpha-2 macroglobulin and complement factor B in patients with nasopharyngeal carcinoma. Electrophoresis 31:14, 2388-2395 Jul 2010 (ISI-Indexed)

2009
  • S.Chandramathi,K.Suresh,Z.B.Anita,U.R.Kuppusamy. Elevated levels of urinary hydrogen peroxide, advanced oxidative protein product (AOPP) and malonaldehyde in humans infected with intestinal parasites.Cambridge University Press. Parasitology (2009) 136, 359-363 (ISI-Indexed)
  • S. Chandramathi, K. Suresh, Z. B. Anita, U. R. Kuppusamy. Attenuation of serum H2O2 and FRAP levels in colorectal cancer patients with intestinal parasitic infection. Mal J Med Sci (2009) 16(2), 15-20 (SCOPUS-Indexed)

2008
  • S.Chandramathi,K.Suresh,Z.B. Anita,U.R.Kuppusamy. Comparative assessment of urinary oxidative indices in breast and colorectal cancer patients. J cancer Res Clin Oncol (2009) 135:319-325 Published online 29 Aug 2008 (ISI-Indexed)
  • Emida Mohamed1 ,Puteri Shafinaz Abdul-Rahman1, Saeid Reza Doustjalali1,Yeng Chen1, Boon-Kiong Lim2, Siti Zawiah Omar2, Anita Zarina Bustam3, Vivek Ajit Singh4, Nur Aishah Mohd-Taib5, Cheng-Har Yip5, Onn Haji Hashim1.1Dept of Molecular Medicine, 2Dept. Of Obstetrics and Gynaecology, 3Clinical Oncology Unit, 4Dept. Of Orthopaedic Surgery, 5Dept. Of Surgery, Faculty of Medicine, University of Malaya. Lectin- based electrophoretic analysis of the expression of the 35 kDa inter- - trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. 2008, 29, 2645-2650 (ISI-Indexed)

2007
  • Nor ZAINAL, Koh HUI, Ting HANG and Anita BUSTAM. Department of Psychological Medicine and Clinical oncology Unit, Faculty of Medicine, Universiti Malaya. Prevalence of distress in cancer patients undergoing chemotherapy. Asia Pacific Journal of Clinical Oncology 2007; 3: 219-223 (Full paper) (ISI-Indexed)

2006
  • Kei Siong Khoo, Syed Hasan Manzoor Zaidi, Vichien Srimuninnimit, Santai Song, Reena Nair, Corazon A. Ngelangel, Anita Bustam, William H.H Reece, Manfred Lehnert.Gemcitabine and split dose paclitaxel or docetaxel in metastatic breast cancer: a randomized phase II study. European Journal of Cancer 42 (2006) 1797-1806 (Full paper) (ISI-Indexed)
  • Saeid R. Doustjali, Rohana Yusof, Gopala K. Govindasamy, Anita Z. Bustam, Bhanumathy Pillay, and Onn H. Hashim. Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. The Journal of Medical Investigation Vol. 53 No. 1,2, February, 2006 (Full paper) (SCOPUS-Indexed)

2005
  • Si Lay Khaing, V Sivaratnam, Siti Zawiah Omar, Anita Zarina Bustam, Mun Kein Seong. Case Report: Small cell carcinoma of uterine cervix in a teen-aged girl a rare occurrence. Malaysian Journal of Obstetrics & Gynaecology 2005: Vol. 8 No. 9: 62-67 (Full paper) (Non-ISI/Non-SCOPUS)
  • R.B. Zain, Raja Latifah RJ, Razak IA, Ismail SM, Atiya SA, Hashim BY, Jallaludin A, Bustam AZ, Rahman ZAA, Krishnan G, Kipli NP, Samsudin AR, Nasir WM, Mahadzir WMW, Abraham MT, Norma J, Tay KK, Yuen KM, Cheong SC and Other MOCRI team members. Oral cancer and Precancer in Malaysia The Database and Tissue Resource Bank. Oral Oncology, MacMillan India; 2005. Vol 10: 3-12 (Full paper) (Non-ISI/Non-SCOPUS)
Proceeding

2006
  • Pawanchek M, Ung N-M*, Bustam A* and Ng K-H. Department of Biomedical Imaging, University of Malaya, *Clinical Oncology Unit, University of Malaya. In-vivo skin dose assessment for breast cancer during radiotherapy treatment using gafchromic film (EBT) detector. Proceedings 29th Annual General Meeting & Scientific Meeting of the College of Radiology Malaysia 3-4 June 2006. (Abstract) 

2005
  • 5. R.B. Zain, R.J. Raja Latifah, I.A. Razak, S.M. Ismail, A.R. Samsuddin, S.A. Atiya, B.Y. Hashim, A. Jallaludin, W.M. Nasir, S.C. Cheong, A.Z.Bustam, W.M.W. Mahadzir, M.T.Abraham, Z.A.A. Rahman, G. Krishnan, N.P. Kipli, J. Norma, K.K. Tay, K.M. Yuen and other MOCRI Team Members. University of Malaya, Universiti Sains Malaysia, Ministry of Health Malaysia, Cancer Research Initiatives Foundation, Malaysia. Oral cancer and precancer research in Malaysia-the database and tissue resource bank. Proceedings of the 10th International Congress on Oral cancer, 19-24th April 2005, Island of Crete, Greece. Oral Oncology Supplement; April 2005; Vol 1 No 1; pp 123 (Abstract) 

2004
  • K.-S. Khoo, M. Zaidi, V. Srimuninnimit, Z. F. Jiang, P. Prem Kumar, A. Bustam, A. H. Villalon, M. Lehnert; National Cancer Centre, Singapore;Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpur, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China.Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC). Vol. 23, 2004 American Society of Clinical Oncology Meeting Proceedings- (Abstract) 

2001
  • Abdul Wahid, A Bustam, F Hayat P Rassiah and U Prasad.Re-treatment of 14 patients with recurrent nasopharyngeal carcinoma using CT simulation and conformal therapy. Radiotherapy and Oncology, Vol. 58 (Supplement1) pg.S97, 6th International Congress of Radiation Oncology Melbourne, Aus, Jan/Feb 2001- (Abstract) 
Others

2003
  • National Clinical Practice Guideline for Breast Cancer Published by MOH/Academy of Medicine Launched in September 2003 

2001
  • Radiation Therapy of Stage IIIB Cervical cancer for Asians ┬┐Report and Guideline from the Cooperative Group Trial. Published by Asia Cooperation Center, Japan Atomic Industrial Forum, Inc. Launched in September 2001 

AREAS OF RESEARCH
(Project title), (Role), (From)-(Until), (Level), (Source).


  • TROIKA study. Neoadj and adjuvant trastuzumab vs biosimilar in HER 2 positive EBC, Principal Investigator(PI), 2018 - 2023, International Funding, (International)
  • MK3475-355 A Randomized, Double-Blind Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Inoperable Locally Recurrent or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355), Principal Investigator(PI), 2016 - 2019, MSD, (International)
  • An In-vivo Optical Fibre Radiation Dosimetry System For The Intrabeamic System In Breast Cancer Patients Undergoing Breast Conserving Surgery Intraoperative Radiotheraphy, Consultant, 2015 - 2018, Geran Penyelidikan Universiti Malaya (UMRG Programme) - HTM (Wellness), (University)
  • A randomised open label phase 3 study of single agent pembrolizumab vs single agent chemo per physician's choice for metastatic triple negative breast cancer-[KEYNOTE-119 study], Principal Investigator(PI), 2015 - 2018, MSD, (International)
  • A Phase III Randomised, Double-Blind,Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting, Co-Investigator, 2014 - 2016, Samsung Bioepis, (International)
  • A Prospective Cohort Study of Patients with Malignant Cord Compression, Co-Investigator, 2014 - 2015, NUS, (International)
  • Oral Cancer Research: Diagnostic And Biobanking Services, Consultant, 2013 - 2015, Geran Penyelidikan Universiti Malaya (UMRG Programme) - HTM (Wellness), (University)
  • Phase II randomized study of docetaxel with or without low-dose, short course sunitinib in the treatment of advanced solid tumors., Co-Investigator, 2013 - 2015, NONE, (University)
  • Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer, Co-Investigator, 2013 - 2015, NONE, (University)
  • JACOB study:A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating The Efficacy and Safety of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patient with HER-2 Positive Metastatic Gastroesophageal Junction and Cancer, Principal Investigator(PI), 2013 - 2015, Roche, (National)
  • ABI-PRO- 3002 A phase 3, randamized, double-blind,placebo-controlled study of abiraterone acetate)JNJ-212082) plus prednisone in asymtomic ormildly symptomatic patients with metastaticcastration-resistant prostate cancer, Co-Investigator, 2012 - 2017, Quintiles Janseen Cilaq, (National)
  • Biobanking of Oral Cancers: An Assessment of Survival, Clinicopathological Parameters, Management Strategies Nutrition and Genetic Susceptibility of Patients, Co-Investigator, 2011 - 2016, High Impact Research (HIR), (National)
  • Lapatinib study Phase II open-labelstudy of preoperativeweeklypac55 litaxel and carboplatinwithlapatinib (Tykerb ) in patientswith ErB2-positive stage I-III Breastc ncer, Co-Investigator, 2011 - 2013, High Impact Research (HIR), (National)
  • Phase 3 open label first line treatment for HER2 positive breast cancer comparing Paclitaxel plus herceptin vs Paclitaxel plus Neratinib., Co-Investigator, 2010 - 2016, Pfizer, (International)
  • HKI 3004 Adjuvant breast cancer study in HER2 positive patients using neratinib., Principal Investigator(PI), 2010 - 2016, Pfizer, (International)
  • D- CARE A Randomised Double- Blind, Placebo- Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence, Principal Investigator(PI), 2010 - 2020, Amgen, (International)
  • ASPECCT Panitumumab vs cetuximab for the third line treatment of advanced colorectal cancer., Co-Investigator, 2010 - 2012, Amgen, (International)
  • ASCOLTAspirin in treating patients with Dukes stage C colon or rectal cancer, or high risk Dukes stage B colon cancer that has been completely removed by surgery., Co-Investigator, 2010 - 2017, NCC Singapore, (International)
  • The Establishment of In-vitro Standard Dose Calibration Curve with High Energy X-ray and Measurement of The Equivalent Dose In Cancer Patients Treated with Radiotherapy Using Biological Dosimetry Technique, Principal Investigator(PI), 2010 - 2011, Postgraduate Research Grant(PPP), (National)
  • AGILE Axitinib in metastatic renal cell carcinoma patients., Co-Investigator, 2010 - 2015, Pfizer, (International)
  • 2009AG-013736 (Axitinib) as Second Line Therapy for Asian Patients with Metastatic Renal Cell Cancer, Co-Investigator, 2009 - 2011, Pfizer, (International)
  • LUME-Lung 2 An international, multi-centre phase III randomised controlled trial for second line treatment of recurrent, advanced non-small cell lung cancer, comparing pemetrexed + placebo versus pemetrexed + BIBF1120 (a multi-targeted tyrosine kinase inhibitor)., Principal Investigator(PI), 2009 - 2012, Boehringer-Ingelheim, (International)
  • A multinational, randomised, open-label, phase 3 study of sunitinib malate vs sorafenib in patients with advanced hepatocellular carcinoma., Co-Investigator, 2008 - 2011, Pfizer, (International)
  • Phase 3b, randomised, open-label study of Bevacizumab + Temsirolimus vs Bevacizumab + Interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma., Co-Investigator, 2008 - 2012, Wyeth, (International)
  • A Phase 2 Biomarker identification Trial for Erlotinib in patients with Advanced Pancreatic carcinoma (MARK study), Principal Investigator(PI), 2008 - 2011, Roche, (International)
  • A prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy. (SHARE Study), Co-Investigator, 2008 - 2010, Short Term Research Fund (Vote F)(PJP), (National)
  • BEATRICE, Principal Investigator(PI), 2008 - 2014, Genentech, (International)
  • Induction and concurrent chemoradiation with cetuximab for treatment of locally advanced Nasopharyngeal Carcinoma, Co-Investigator, 2008 - 2012, Geran Penyelidikan Universiti Malaya (UMRG), (National)
  • An international multi-centre phase III randomised controlled trial of first line treatment of advanced renal cell carcinoma, comparing bevacizumab + interferon-alpha versus bevacizumab + torisel., Co-Investigator, 2008 - 2012, Wyeth, (National)
  • A Prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy (SHARE Study), Co-Investigator, 2008 - 2010, Geran Penyelidikan Universiti Malaya (UMRG), (National)
  • A phase 3 multicentre, randomised, placebo- controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer., Co-Investigator, 2007 - 2010, Genentech, (National)
  • A Phase II, Open-label, Randomised, Multicenter Trial of GW786034 (Pazopanib) in combination with Lapatinib (GW 572016) compared to Lapatinib alone as first line therapy in subjects with advanced or metastatic breast cancer with erb-B2 FISH positive tumours., Co-Investigator, 2007 - 2008, GSK, (International)
  • A multi-institutional study on the clinical outcome of patients with nasopharyngeal carcinoma (NPC) and the establishment of a Malaysian NPC tissue bank., Co-Investigator, 2007 - 2008, MOH, (National)
  • Development of Risk Models and Management Strategies for Oral Cancer, Co-Investigator, 2007 - 2015, ScienceFund, (National)
  • SATURN/TITAN- A Multicentre, double blind randomized phase 3 study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented or advanced or recurrent or metastatic NSCLC who have not experienced disease progression or unacceptable toxicity during chemotherapy, Principal Investigator(PI), 2006 - 2011, Roche, (International)
  • A Phase III trial of novel Epothilone BMS-247550 plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant., Principal Investigator(PI), 2005 - 2008, BMS, (International)
  • Phase II, open label study of SB-715992 in subjects with advanced or metastatic breast cancer., Co-Investigator, 2004 - 2008, GSK, (International)
  • Oral cancer and precancer in Malaysia-risk factors, prognostic markers, genetic expression and impact on quality of life., Co-Investigator, 2004 - 2015, IRPA, (National)
  • Concurrent weekly Cisplatin and radiotherapy for advanced cervical cancer., Co-Investigator, 2003 - 2008, FNCA, Japan, (International)
  • Randomised Phase 2 trial of Gemcitabine combined with a Taxane for metastatic breast cancer., Principal Investigator(PI), 2001 - 2003, Eli Lilly, (International)
  • Clinical trials any solid tumour in particular breast cancer.

CONSULTATION PROJECT/CONSULTANCY
(Project title), (Role), (From)-(Until), (Organisation).


  • Collaborations of Radiation Oncology in Asia, 2016-2016, JASTRO
  • Eribulin in breast cancer treatment, 2013-2013, Eisai Malaysia Sdn Bhd
  • The treatment outcome of radical radiotherapy in laryngeal cancer, 2013-2013, BIIJ
  • MEASUREMENT OF BLADDER VOLUME VARIATIONS USING PORTABLE ULTRASOUND EQUIPMENT: INTRODUCTION OF DRINKING PROTOCOL, 2013-2013, BIIJ
  • Penilaian ubat-ubatan kemoterapi, 2012-2012, UMMC
  • Head of panel of judges for oral presentations at ASCOMOS 2012, 2012-2012, Malaysian Oncological Society
  • Radiation Oncology training in Malaysia, 2012-2012, IAEA
  • Erlotinib in first line EGFR mutation positive NSCLC, 2012-2012, Roche
  • Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC), 2012-2012, MJM
  • Radioimmunotherapy-Based Treatment of Cancer, 2011-2011, BIIJ
  • Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer, 2009-2009, BIIJ
  • Poster presentations MOS 2008, 2008-2008, Malaysian Oncological Society
  • Asia Pacific Cancer Conference 2011, 2008-2008, Malaysian Oncological Society
  • Medulloblastoma: Cranial spinal junctional techniques., 2008-2008, BIIJ
  • International Atomic Energy Agency (IAEA) Project RCA RAS 6040 Improvement in Quality of Radiotherapy for Frequent Cancers in the Region ., 2005-2005, International Atomic Energy Agency (IAEA)
  • Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) PhD(Diagnostic Imaging)(UKM) PhD(Radiotherapy)(UKM), 2003-2003, UKM
  • 37th Malaysia-Singapore Congress of Medicine, 2003-2003, Academy of Medicine
  • National cancer registry, 2003-2003, Ministry of Health
  • Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) PhD(Diagnostic Imaging)(UKM) PhD(Radiotherapy)(UKM), 2003-2003, UKM
  • MOS Annual Scientific Meeting, 2001-2001, Malaysian Oncological Society
  • Annual Scientific meetings, 2001-2001, Malaysian Oncological Society

AWARDS AND RECOGNITIONS
(Name of Award), (Awarding Institution), (Year Awarded), (Level).


  • Appreciation Letter, Faro 2018 Organising Committee, 2018, (International)
  • Live Surgery Iort Workshop, College of Surgeons and Academy of Medicine Malaysia, 2017, (National)
  • Certificate of Appreciation, Ummc, 2017, (National)
  • Letter of Appreciation, Universiti Malaya, 2016, (University)
  • Certificate of Appreciation, Maspho, 2016, (National)
  • Certificate of Appreciation, Malaysian Psychiatric Association, 2016, (National)
  • Certificate of Excellent Service, University Malaya, 2014, (University)
  • Appreciation, Ummc, 2014, (Community)
  • Khidmat Setia 20 Award, 2013
  • Excellence Service Award, University Malaya, 2012, (University)
  • Appreciation, Iaea, 2012, (National)
  • Anugerah Khidmat Cemerlang, Universiti Malaya, 2012, (University)
  • Excellence Service Award, University Malaya, 2009, (University)
  • Anugerah Khidmat Cemerlang, Universiti Malaya, 2009, (University)
  • Eskpo Penyelidikan, Rekacipta Dan Inovasi UM 2009, Universiti Malaya, 2009, (University)
  • Certificate of Excellent Service, University Malaya, 2007, (University)
  • Appreciation, Dept of Biomedical Imaging, Ummc, 2007, (University)
  • Appreciation, National Cancer Registry, 2007, (National)
  • Excellence Service Award, University Malaya, 2006, (University)
  • Anugerah Khidmat Cemerlang, Universiti Malaya, 2006, (University)
  • Bronze Medal for The Category of Fundamental Research: Oxidative Stress Biomarkers in Breast Cancer. Eskpo Penyelidikan, Rekacipta Dan Inovasi 2006, 18-20 Julai, Universiti Malaya, 2006, (University)
  • Certificate of Excellent Service, University Malaya, 2005, (University)
  • Gold Medal for The Category of Invention & Innovation Sempena Eskpo Penyelidikan, Rekacipta Dan Inovasi 2005, 14-17 Jun. Oral Cancer Database Software- Real and Virtual Tumor Bank System (Ocds/Rvtbs)- An Aid for Multicenter Studies., Universiti Malaya, 2005, (University)
  • Appreciation, Ministry of Health, 2004, (National)
  • Appreciation, Mitc, Ummc, 2004, (University)
  • Appreciation, Moh, 2004, (National)
  • Excellence Service Award, University Malaya, 2003, (University)
  • Appreciation, National Cancer Registry, 2003, (National)
  • Anugerah Khidmat Cemerlang, Universiti Malaya, 2003, (University)
  • Anugerah Khidmat Cemerlang, Universiti Malaya, 2002, (University)
  • Anugerah Khidmat Cemerlang, Universiti Malaya, 2001, (University)

PRESENTATIONS
(Title), (Event), (Date Presented), (Organiser), (Level).


INVITED SPEAKER
  • Hormone therapy, Oncology in Palliative Care Seminar, 2001-07-29 to  , Hospis Malaysia, (National)
  • Follow-up of treated breast cancer patients, MOS Annual Scientific Meeting, 2002-09-20 to 2002-09-22, MOS, (National)
  • Radiotherapy of BAVM, Basic Neuro-interventional Course, 2004-03-11 to 2004-03-12, Radiology Dept, FOM, UM, (University)
  • An overview of radiation therapy in cancer treatment., A Continuous Professional Development Course in Radiotherapy, 2005-12-20 to 2005-12-22, Radiology Dept., FOM, UM, (National)
  • Oncology Endpoints: Their relevance in advanced cancer. , Palliative Care Symposium: Clinical Decision making and Ethics in Advanced Cancer, 2007-04-18 to  , Faculty of Medicine, UM, (National)
  • Pengenalan Kanser Wanita dan Rawatan, Seminar kanser wanita dari perspektif biopsikososial, 2008-11-11 to  , PTj Kebajikan Perubatan, PPUM, (National)
  • Radiation Therapy for cancer, Seminar perawatan Onkologi, 2010-09-28 to 2010-09-28, PTj Pembangunan Insan, (University)
  • clinical research forum, 5th national conference on clinical research, 2011-06-24 to 2011-06-24, ministry of health malaysia, (National)
  • Radiotherapy planning for breast cancer, Moving from 2D to 3D conformal radiotherapy workshop IAEA MAL 6020, 2012-06-20 to 2012-06-22, MOH, (National)
  • Recurrent and metastatic NPC: issues and challenges, NPC research day, 2013-03-04 to 2013-03-04, NPC Society Malaysia/Universiti Malaya, (National)
  • An overview of cancer services in Malaysia; a virtual tour of Clin Onco Dept UMMC ; Oncology training in Malaysia, Department of Radiation Oncology, Technical University Munich Seminar, 2014-04-04 to 2014-04-04, Department of Radiation Oncology, Technical University Munich, (International)
  • Hormonal therapy in breast cancer, 1st UMMC breast cancer public forum, 2014-10-18 to 2014-10-18, Breast cancer resource centre,UMMC
  • Development of oncology training in middle income countries: the Malaysian model, AROICON 2015, 2015-11-29 to 2015-11-29, AROI, (International)
  • Epidemiology of cancer and current treatment modalities, 20th Malaysian Conference on Psychological Medicine, 2016-06-03 to 2016-06-03, Malaysian Psychiatric Association, (National)
  • RADIATION THERAPY IN NEUROBLASTOMA, MASPHO ASM 2016, 2016-11-05 to 2016-11-06, MASPHO, (National)
  • Antimetabolites, Masterclass in Systemic Cancer Therapy, 2017-03-04 to 2017-03-05, Dept of Clinical Oncology, UMMC, (National)
  • IORT in breast cancer, Live surgery IORT workshop, 2017-08-24 to 2017-08-25, Dept of Surgery, UMMC, (International)
  • Antimetabolites, MSCT 2018, 2018-03-09 to 2018-03-10, Clinical Oncology Dept, UMMC, (National)
  • IORT in breast cancer, FARO Annual Meeting 2018, 2018-09-06 to 2018-09-08, Indonesia radiation oncology society, (International)
PRESENTER
  • Concurrent chemoradiotherapy for cervical cancer (CERVIX-III), FNCA workshop on Radiation Oncology, 2004-12-13 to 2004-12-17, FNCA, (International)
  • Key Performance Indices , Ministry of Health Workshop on Quality Assurance in Radiotherapy , 2006-08-01 to  , MOH, (National)
  • Clinical Oncology training in Malaysia, 1st FARO Council Member meeting, 2015-05-30 to 2015-05-30, Japan as host country, (International)
EVENT ORGANISER
  • None, MOS Annual Scientific Meeting, 2002-09-28 to 2001-09-30, MOS, (National)
  • Not applicable, APCC 2011, 2011-11-10 to 2011-11-11, MOS, (International)
POSTER
  • DEVELOPMENT OF SPECIALIST TRAINING PROGRAMME IN CLINICAL ONCOLOGY: THE MALAYSIA EXPERIENCE, ICARO 2009, 2009-04-27 to 2009-04-29, IAEA, (International)
  • Psycho-Oncology Referrals- A Single-Centre Review from Malaysia, IPOS 12th World Congress of Psycho-Oncology, 2010-05-25 to 2010-05-29, (International)
  • Prospective controlled study on the role of scalp hypothermia to prevent chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy., APCC 2011, 2011-11-10 to 2011-11-11, MOS, (International)
  • Outcome of malignant CNS tumours in young children from a single institution in Malaysia: 15-year experience with HEAD START 1 and 2 protocols, SIOP 2018, 2018-11-16 to 2018-11-18, SIOP, (International)
OTHERS
  • None, 37th Malaysia-Singapore Congress of Medicine, 2003-09-05 to 2003-09-07, Academy of Medicine, (National)
  • Report on Lung cancer statistics, NCR Report Writing Workshop for year 2003-2005, 2007-03-02 to 2007-03-04, MOH, (National)
  • Oral presentations, ASCOMOS 2012, 2012-09-08 to 2012-09-08, MOS, (National)
  • Jacob study for stomach cancer, JACOB study Investigator Meeting, 2013-03-06 to 2013-03-08, Roche, (International)
  • Breast cancer, Asia Pacific Breast Cancer Summit, 2013-04-12 to 2013-04-13, (International)
  • Lung cancer, World conference on lung cancer, 2013-10-27 to 2013-10-30, IASLC, (International)
  • not applicable, ESMO Penang, 2015-01-22 to 2015-01-25, MOS and ESMO, (International)

EXPERT/TECHNICAL CONTRIBUTIONS
(Activity), (Organisation), (Role), (From)-(Until), (Level).


  • Evaluate the suitability of eribulin in patients who have failed one line of chemo in the advanced metastatic setting., Drug Control Authority, MOH Malaysia, Expert Advisor, 2018-2018, (National)
  • RCA-IAEA project RAS6086 - Strengthening cancer management programmes in RCA states parties through collaboration with national and regional radiation oncology societies., IAEA, Coordinator, 2018-2018, (National)
  • Evaluate the suitability of TS-1 tablet in terms of bioequivalence as compared to TS-1 capsule to be used for the same clinical indications., DCA, MOH, Expert Advisor, 2017-2017, (National)
  • Evaluate the suitability of cyramza in the treatment of stomach/GOJ tumours, colorectal and NSCLC for the purpose of registration., National Pharmaceutical Control Bureau, MOH Malaysia, Expert Advisor, 2016-2016, (National)
  • Evaluate the suitability of tegafur in the treatment of colorectal cancer for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia, Expert Advisor, 2016-2016, (National)
  • Evaluate suitability of research project/proposal for consideration of sciencefund(MOSTO) research grant, Universiti Malaya, Evaluator, 2016-2016, (University)
  • Evaluate the suitability of afinitor in the treatment of advanced renal cell carcinoma in patients with disease progression following treatment with anti VEGF, Drug Control Authority, Ministry of Health, Malaysia, Expert Advisor, 2016-2016, (National)
  • Evaluate the suitability of tegafur in the treatment of pancreatic cancer for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia, Expert Advisor, 2016-2016, (National)
  • Evaluate the suitability of tegafur in the treatment of NSCLC for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia, Expert Advisor, 2016-2016, (National)
  • Evaluate suitability of vismodegib in advanced basal cell carcinoma for the purpose of new drug registration., Pihak Berkuasa Kawalan Dadah Biro Pengawalan Farmaseutikal Kebangsaan Kementerian Kesihatan Malaysia, Expert Advisor, 2015-2015, (National)
  • Evaluate suitability of nindetanib esilate in advanced NSCLC for the purpose of new drug registration., Pihak Berkuasa Kawalan Dadah Biro Pengawalan Farmaseutikal Kebangsaan Kementerian Kesihatan Malaysia, Expert Advisor, 2015-2015, (National)
  • Root cause analysis, UMMC, Committee Member, 2013-2013, (Hospital Level)
  • Penilaian ubat-ubatan kimoterapi, Pusat perubatab Universiti Malaya, Committee Member, 2012-2012, (University)
  • Radiation oncology curriculum in developing countries, IAEA, Consultant, 2012-2012, (International)
  • Clinical Oncology Specialty Committee, Universiti Malaya, Chairman, 2009-present, (National)
  • Organising Committee for APCC 2011, Malaysian Oncological Society, Committee Member, 2008-present, (National)
  • To give input with regards to the conduct and management of clinical trials and in particular industry sponsored trials managed by Clinical Investigation Centre, UM, Clinical Investigation Centre, Faculty of Medicine , UM, Committee Member, 2005-Present, (University)
  • International Atomic Energy Agency (IAEA) Project Coordinator for project RCA RAS 6040 Improvement in Quality of Radiotherapy for Frequent Cancers in the Region., IAEA, Coordinator, 2005-2009, (International)
  • Structuring, data collection, analysis and report writing, National Cancer Registry, Advisor, 2003-2007, (National)
  • Medical Advisory Committee member. Advise on clinical issues at UMMC., UMMC, Committee Member, 2001-Present, (University)

EVALUATION ACTIVITIES
(Description), (Evaluation Activity),(Year).


  • Marking Part 2 COQ exam scripts. Examiner for Final Examination, Master Of Clinical Oncology Exam ,  (2019 - 2019)
  • Jawatankuasa Pemeriksa bagi Peperiksaan ljazah Sarjana Sains Perubatan secara Penyelidikan /Kursus dan Penyelidikan (bagi komponen penyelidikan) i)Berkaitan dengan peperiksaan disertasi, menimbang laporan pemeriksa di atas disertasi seorang calon dan mengambil sesuatu keputusan termasuk mengenai tahap pencapaian disertasi itu ; ii) Dalam keadaan tertentu Jawatankuasa Pemeriksa boleh menjalankan peperiksaan viva dan / atau ujian lain difikirkan sesuai ; dan iii) Melaporkan kepada Senat mengenai apa-apa perkara yang berkaitan dengan mutu dan/atau perjalanan sesuatu peperiksaan., Thesis ,  (2019 - 2019)
  • Intracranial angiomatoid Fibrous histiocytoma with Hodgkin lymphoma, Article In Journal ,  (2018 - 2018)
  • The Great Masquerade: Empyema Thoracis as an Unusual Presentation of Primary Lung Malignancy, Article In Journal ,  (2018 - 2018)
  • Comparison of the seventh and eight editions of the UICC/AJCC staging system for NPC; analysis of 1317 patients treated with IMRT at two centres, Article In Journal ,  (2017 - 2017)
  • Chemotherapy for metastatic colon cancer -No effect on survival when the dose is reduced due to side-effects. BMC cancer, Article In Journal ,  (2017 - 2017)
  • Marking MCO Part 1 exam scripts, Exam Script ,  (2017 - 2017)
  • Outcome of patients with cord compression treated in UMMC. Master of Clinical Oncology Final Exam, Thesis ,  (2017 - 2017)
  • Review and select abstracts for FARO 2017 scientific meeting, Abstracts ,  (2017 - 2017)
  • Ref.: Ms. No. MJM-D-17-00148 Breast Ductal Carcinoma to Metaplastic Carcinoma- A Change in Cancer Morphology - A Case Report and Literature Review The Medical Journal of Malaysia, Article In Journal ,  (2017 - 2017)
  • "Stress levels during the journey of cancer treatment", Article In Journal ,  (2017 - 2017)
  • Marking of exam scripts for Master of Clinical Oncology Part 1 May 2017 Exam, Exam Script Marker ,  (2017 - 2017)
  • Examiner for MD degree. Title of thesis: Management of psychological distress in cancer patients. MHB130001, Thesis ,  (2017 - 2017)
  • Lapatinib, trastuzumab and Capecitabine prolonged the survival of HER2-positive gastric cancer with leptomeningeal carcinomatosis: a case report., Article In Journal ,  (2017 - 2017)
  • Evaluation of research proposal under FRGS grant application, Frgs Grant ,  (2017 - 2017)
  • Relapsed Lymphoma Mimicking Venous Ulcer : A Case report for MJM, Article In Journal ,  (2017 - 2017)
  • Peperiksaan OSCE Stage 2 MBBS - RSA 1, Osce Stage 2 Mbbs Exam ,  (2017 - 2017)
  • Review research abstracts submitted for FARO 2016. Provide scoring for each as per guideline from organising commitee., Abstracts ,  (2016 - 2016)
  • Pretreatment Expression of Blood and Tissue Biomarkers as a Predictor of Tumor Response After Neoadjuvant Chemoradiation in Rectal Cancer, Article In Journal ,  (2016 - 2016)
  • Evaluate the suitability of the following article for publication in BMC Cancer journal: Chemotherapy on metastatic colon cancer:No effect on survival when dose is reduced due to side-effects., Article In Journal ,  (2016)
  • Management of psychological distress in cancer patients: Focus on brief mindful therapy, Phd Seminar Proposal ,  (2016)
  • Medical Journal Malaysia: Gastric ulcer than turned out to be metastasis of a synovial sarcoma: A case report and literature review., Article In Journal ,  (2016)
  • Chemotherapy Induced Neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort Study, Article In Journal ,  (2016)
  • Evaluate suitability of research proposal/project for consideration of sciencefund (MOSTI) research grant, Project ,  (2016)
  • Master of Clinical Oncology Part 1, 2 and Final Exams, Prepare Exam Questions And Mark Exam Scripts ,  (2016)
  • Treatment Of heavily pre-treated metastatic breast cancer with Eribulin: First local experience in Sabah., Article In Journal ,  (2016)
  • Triple negative breast cancer survival and prognostic factors., Thesis ,  (2016)
  • marking exam scripts and viva voce, Master Of Clinical Oncology ,  (2015)
  • Palliative to curative treatment: A case of stage 4 mucinous adenocarcinoma successfully treated with metronomic capecitabine in combination with bevacizumab and surgery., Article In Journal ,  (2015 - 2015)
  • Symptoms burden and QoL. Comparison between CAM and non-CAM users during breast cancer chemotherapy in 2 public hospitals in Malaysia., Thesis ,  (2015 - 2015)
  • Editorial board member for International Journal of Recent Research in Life Sciences (IJRRLS), Article In Journal ,  (2014)
  • JUMMEC Case study: Squinting eyes: A presenting complaint in a young adult with glioblastome multiforme., Article Reviewer ,  (2013 - 2013)
  • Metastatic melanoma to the stomach; a case report, Article Reviewer ,  (2013 - 2013)
  • Survival of primary lung cancer patients treated in Brunei darussalam, Article Reviewer ,  (2013 - 2013)
  • MJM Chemotherapy extravasation at Hospital Pulau Pinang Malaysia, Article Reviewer ,  (2013 - 2013)
  • The treatment outcome of radical radiotherapy in laryngeal cancer., Article Reviewer ,  (2013 - 2013)
  • Master of Clinical Oncology Part 1,2 and Final Exam, Mark Exam Scripts And Conduct Clinical Exam ,  (2013)
  • Appointed as external assessor from UCSI University to assess suitability of an academic staff from UCSI for promotion from assoc. prof. to full prof., To Assess Suitability Of Candidate For Promotion ,  (2013 - 2013)
  • MEASUREMENT OF BLADDER VOLUME VARIATIONS USING PORTABLE ULTRASOUND EQUIPMENT: INTRODUCTION OF DRINKING PROTOCOL, Article In Journal ,  (2013 - 2013)
  • Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC), Article In Journal ,  (2012 - 2012)
  • Induction chemotherapy with paclitaxel, ifosfamide and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer., Article In Journal ,  (2009 - 2009)
  • Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) PhD(Diagnostic Imaging)(UKM) PhD(Radiotherapy)(UKM), Academic Programme Evaluator ,  (2008 - 2008)
  • Poster presentations, Judge For Poster Presentations ,  (2008 - 2008)
  • Medulloblastoma: Cranial spinal junctional techniques., Article Reviewer ,  (2008 - 2008)
  • Advanced Diploma in Nursing Oncology (UM), Programme Evaluator ,  (2008 - 2008)
  • Master of Clinical Oncology Part 1 Exam, Internal Examiner ,  (2006)

CONTRIBUTION TO SOCIETY
(Contribution To Society), (Level), (Start Date), (End Date).


  • Breast cancer public forum, (Community), 18/10/2014 until 18/10/2014
  • SMK Seksyen 9 Shah Alam Niners A+ committee member, (Community), 01/07/2013 until 12/10/2013
  • Women's Integration Society, (Local), 01/01/2002 until  

INTELLECTUAL PROPERTY RIGHTS
(Product Name), (Type), (Reference), (Year), (Level).


  • Master of Clinical Oncology Programme Syllabus, literary work, 08/11/2013, (UNIVERSITY)

SUPERVISION


POST GRADUATE STUDENT
(Name of Degree), (Name of Candidates), (Title of Thesis), (Academic Session)

Ongoing
  • Master Degree, Jason Lai Shen Chang, Clinical supervision, 2019/2020
  • Master Degree, Mohd Fahim Abd Rahman, Clinical supervision, 2019/2020
  • Master Degree, Sum Ying Ying, Clinical supervision, 2019/2020
  • Master Degree, Mohd Fahim Abd Rahman, clinical supervision, 2019/2020
  • Master Degree, Nor Hayati Hashim, Clinical supervision, 2019/2020
  • Master Degree, Nor Hayati Hashim, clinical supervision, 2019/2020
  • Master Degree, Shazlin Hasbullah, clinical supervision, 2019/2020
  • Master Degree, Shazlin Md Hasbullah, Clinical supervision, 2019/2020
  • Master Degree, Tun Mohd Azlan Mohd Nor, Clinical supervision, 2019/2020
  • Master Degree, Jason Lai Shen Chang, clinical supervision, 2019/2020
  • Master Degree, Sum Ying Ying, clinical supervision, 2019/2020
  • Master Degree, Tun Mohd Azlan Mohd Nor, clinical supervision, 2019/2020
  • Master Degree, Chiam Poh Jeann, Clinical supervision, 2018/2019
  • Master Degree, Ahmad Naufal Md Alwi, Clinical supervision, 2018/2019
  • Master Degree, Noor Nabila Mohamed, Clinical supervision, 2018/2019
  • Master Degree, Nisha Mohd Shariff, Clinical supervision, 2018/2019
  • Master Degree, Tang Seng Paul, Clinical supervision, 2018/2019
  • Master Degree, Teh Hooi Lay, Timing And Outcome Of Palliative Chemotherapy, 2017/2018
  • Master Degree, Rosdiana, clinical supervision, 2017/2018
  • Master Degree, Syadwa, clinical supervision, 2017/2018
  • Master Degree, Puvaneswarry, clinical supervision, 2017/2018
  • Master Degree, Mohd Asyraf, clinical supervision, 2017/2018
  • Master Degree, Patricia Shamani, clinical supervision, 2017/2018
  • Master Degree, Eng Jie Yi, clinical supervision, 2017/2018
  • Master Degree, Kumutha, Acute radiation related oral toxicities in HNSCC patients in UMMC: A prospective study, 2017/2018
  • Master Degree, Syadwa, Palliative radiotherapy for advanced cancer: Are we giving it to the right patient at the right time?, 2017/2018
  • Master Degree, Teh Hooi Lay, clinical supervision, 2017/2018
  • Master Degree, Heng Fook Yew, Chemoport usage and complication rates in UMMC., 2017/2018
  • Master Degree, Aldrin Jasper, clinical supervision, 2017/2018
  • Master Degree, Tan Li Mei, clinical supervision, 2017/2018
  • Master Degree, Kumutha, clinical supervision, 2017/2018
  • Master Degree, Lavannia, clinical supervision, 2016/2017
  • Master Degree, Fiona, clinical supervision, 2016/2017
  • Master Degree, Chan Ming Jun, clinical supervision, 2016/2017
  • Master Degree, Vance Koi, clinical supervision, 2016/2017
  • Master Degree, Hadi, clinical supervision, 2016/2017
  • Master Degree, Lee Hong Moi, clinical supervision, 2016/2017
  • Master Degree, Tan Li Mei, clinical supervision, 2016/2017
  • Master Degree, Syafirin, clinical supervision, 2016/2017
  • Master Degree, Sangeeta, clinical supervision, 2016/2017
  • Master Degree, Lee Dai Wee, clinical supervision, 2016/2017
  • Master Degree, Nik Rozlin Elini Mohd Shuhaimi, clinical supervision, 2015/2016
  • Master Degree, Syazni Badrol Hisham, clinical supervision, 2015/2016
  • Master Degree, Heng Fook Yew, Chemoport usage and its complications in the oncology dept, UMMC, 2015/2016
  • Master Degree, Ngu Ming Ruey, clinical supervision, 2015/2016
  • Master Degree, Hadi Jalil, clinical supervision, 2015/2016
  • Master Degree, Alagu Manthiram Ramasamy, clinical supervision, 2015/2016
  • Master Degree, Nur Jihan Irwan Tan, clinical supervision, 2015/2016
  • Master Degree, Lee Hong Moi, clinical supervision, 2015/2016
  • Master Degree, Heng Fook Yew, clinical supervision, 2015/2016
  • Master Degree, Kumutha A/p Chalaya, clinical supervision, 2015/2016
  • Master Degree, Rosdiana Abd Rahim, clinical supervision, 2015/2016
  • Master Degree, Nisha Mohd Shariff, clinical supervision, 2015/2016
  • Master Degree, Gan Ben Jin, Clinical supervision, 2014/2015
  • Master Degree, Lim Yi Way, Clinical supervision, 2014/2015
  • Master Degree, Lim Yaeh Ni, Clinical supervision, 2014/2015
  • Master Degree, Shadwa, Clinical supervision, 2014/2015
  • Master Degree, Syadwa, Timing and outcome of palliative radiotherapy., 2014/2015
  • Master Degree, Fiona Suling Lian, Clinical supervision, 2013/2014
  • Master Degree, Choong Swee Hsia, Clinical supervision, 2013/2014
  • Master Degree, Tan Li Mei, Clinical supervision, 2013/2014
  • Master Degree, Noor Zafifah Zakaria, Clinical supervision, 2013/2014
  • Master Degree, Khairiyah Sidek, Clinical supervision, 2013/2014
  • Master Degree, Teo Yin Keong, Clinical supervision, 2013/2014
  • Master Degree, Sow We Jen, Clinical supervision, 2013/2014
  • Master Degree, Prathepamalar Yehgambaram, Clinical supervision, 2012/2013
  • Master Degree, Santhi Nadarajan, Clinical Supervision, 2011/2012
  • Master Degree, Soma Bavani Sivaraj, Clinical supervision, 2011/2012
  • Master Degree, Winnie Ng Nyek Ping, Clinical supervision, 2011/2012
  • Master Degree, Ng Boon Huat, Clinical supervision, 2011/2012
  • Master Degree, Ina Shaliny Duraisamy, Clinical supervision, 2011/2012
  • Master Degree, Tan Chih Kiang, Clinical supervision, 2010/2011
  • Master Degree, Arnil George Sirimanne, Clinical supervision, 2010/2011

Completed
  • Master Degree, Sucharit Pongprakyun, Clinical supervision, 2012/2013
  • Master Degree, Eznal Izwadi Mohd Mahidin, Clinical supervision, 2012/2013
  • Master Degree, Harissa Husainy Hasbullah, adjuvant trastuzumab in early breast cancer: a`retrospective cohort study in two oncology centres in malaysia, 2012/2013
  • Master Degree, Ang Tick Suan, Clinical supervision, 2012/2013
  • Master Degree, Tang Weng Heng, Clinical supervision, 2011/2012
  • Master Degree, Junie Khoo Yu Yen, Clinical supervision, 2011/2012
  • Master Degree, Marfuah Nik Eezamuddeen, Clinical supervision, 2011/2012
  • Master Degree, Nahjatul Kursyiah Abd Ghafar, Clinical supervision, 2011/2012
  • Master Degree, Leong Siew Mooi, Clinical supervision, 2010/2011
  • Master Degree, Lim Chun Sen, Radiation-induced hypothyroidism following radical radiotherapy for head and neck cancer, 2010/2011
  • Master Degree, Halim Abdul Rahman, The Establishment of In-vitro Standard Dose Calibration Curve with High Energy X-ray and Measurement of The Equivalent Dose In Cancer Patients Treated with Radiotherapy Using Biological Dosimetry Technique, 2010/2011
  • Master Degree, Wong Yoke Fui, Clinical supervision, 2010/2011
  • Master Degree, Malwinder Singh Sandhu, Clinical supervision, 2010/2011
  • Master Degree, Vaishnavi Jeyasingam, Clinical supervision, 2009/2010
  • Master Degree, Nor Aziyan Yahya, Symptoms prevalence, characteristics and coping strategies among adult oncology patients., 2009/2010
  • Master Degree, Muthukumaran, Clinical supervision, 2009/2010
  • Master Degree, Harissa Husainy Hasbullah, Clinical supervision, 2009/2010
  • Master Degree, Fong Chin Heng, Clinical supervision, 2008/2009
  • Master Degree, Cheah Soon Keat, Clinical supervision, 2008/2009
  • Master Degree, Mastura Md Yusuf, Concurrent chemoradiotherapy in H&N cancer, 2008/2009
  • Master Degree, Natasha Mohd Hashim, Clinical supervision, 2008/2009
  • Master Degree, Suhana Yusak, Clinical supervision, 2008/2009
  • Master Degree, Ibtisam Muhammad Nur, Clinical supervision, 2007/2008
  • Master Degree, Hafizah Zaharah Ahmad, Clinical supervision, 2007/2008
  • Master Degree, Lee Wei Ching, Clinical supervision, 2007/2008
  • Master Degree, Ramarao A/l Seriramalu, Proteomic studies in patients with NPC: lectin-based approach, 2007/2008
  • Master Degree, Vincent Phua Chee Ee, Analysis of breast cancer in elderly women:cohort of 1994-2004 treated in UMMC, 2007/2008
  • Master Degree, Flora Chong Li Tze, Clinical supervision, 2007/2008
  • Master Degree, Nik Muhd Aslan Abdullah, Concurrent chemoradiation for patients with nasopharyngeal carcinoma treated in UMMC between 2001 and 2003., 2006/2007
  • Master Degree, Yu Kong Leong, Clinical supervision, 2006/2007
  • Master Degree, Lau Kah Liew, Clinical supervision, 2006/2007
  • Master Degree, Ros Suzanna Ahmad Bustamam, Clinical supervision, 2006/2007
  • Master Degree, Hayani Abdul Wahid, Clinical supervision, 2006/2007
  • Master Degree, Kua Voon Fong, Cinical supervision, 2005/2006
  • Master Degree, Chan Wee Han, Clinical supervision, 2005/2006
  • Master Degree, Mahzom Pawanchek, In vivo skin dose assessment for breast cancer dring radiotherapy treatment using gafchromic film (EBT) detector, 2005/2006
  • Master Degree, Rozita Abdul Malik, Clinical supervision, 2004/2005
  • Master Degree, Sin Sze Yarn, The evolution of 2-D to 3-D radiation therapy practice in the treatment of nasopharyngeal carcinoma., 2004/2005
  • Master Degree, Fabian Lee Wei Yuen, Clinical supervision, 2004/2005
  • Master Degree, Wan Zamaniah Wan Ishak, Clinical supervision, 2004/2005
  • Master Degree, Si Lay Khaing, Assessment of patients with carcinoma of the cervix treated with definitive radiotherapy at UMMC., 2003/2004
  • Master Degree, Azura Deniel, Clinical supervision, 2002/2003
  • Master Degree, Mohd Azhar Musa, Dosimetric comparison of the Enhanced Dynamic Wedge and the Physical Wedge and its clinical implications

Terminated
  • Master Degree, Felix Liau Yee Fan, clinical supervision, 2015/2016
  • Master Degree, Ravivarma Prathapan, clinical supervision, 2015/2016
  • Master Degree, Narendran K, Clinical supervision, 2014/2015
  • Master Degree, Narendran, Timing and outcome of palliative chemotherapy, 2014/2015
  • Master Degree, Han Albert Dicken, Clinical supervision, 2011/2012
  • Master Degree, Astrid Sinarti Hassan, Clinical supervision, 2010/2011
  • Master Degree, Sunitha Kumaran, Clinical supervision, 2010/2011
  • Master Degree, Noor Syuhadah A. Karim, Clinical supervision, 2009/2010
  • Master Degree, Atiliana Mohamed Adib, Clinical supervision, 2009/2010
  • Master Degree, Noorzulali Haron, Clinical supervision, 2008/2009
  • Master Degree, Siti Zaleha Md Sani, Clinical supervision, 2008/2009
  • Master Degree, Chandra Kumar A/l Krishnan, Clinical supervision, 2005/2006
  • Master Degree, Ng Poh Huat, Clinical supevision, 2005/2006
  • Master Degree, Yang Rashidi Abdullah, Clinical supervision, 2004/2005
  • Master Degree, Adlan Suhaimi Ahmad, Clinical supervision, 2003/2004
  • Master Degree, Tan Boon Seang, Clinical supervision, 2003/2004
  • Master Degree, Farah Zaffar Hayat, Clinical supervision, 2002/2003
FIRST DEGREE/DIPLOMA/PRE-DEGREE
(Course Title), (Academic Session), (No. of Candidates)

Completed
  • Describing the clinical management and resource use of solid tumour patients with chemotherapy-related febrile neutropenia in UMMC, 2012/2013, 1

TEACHING
(Course Title), (Academic Session), (No of Student), (No of Contact Hours).


POST GRADUATE
  • MASTER OF CLINICAL ONCOLOGY, 2017/2018(1), 5, 260
  • MASTER OF CLINICAL ONCOLOGY, 2016/2017, 8, 520
  • MASTER OF CLINICAL ONCOLOGY, 2016/2017, 8, 6
  • Master of Clinical Oncology, 2015/2016, 7, 6
  • MASTER OF CLINICAL ONCOLOGY, 2015/2016, 11, 520
  • Master of Clinical Oncology, 2014/2015, 11, 524
  • Master of Clinical Oncology, 2013/2014, 16, 110
  • Master of Clinical Oncology, 2012/2013, 12, 524
  • Master of Medical Physics, 2012/2013, 7, 2
  • Master of Clinical Oncology, 2011/2012, 10, 532
  • Master of Medical Physics, 2011/2012, 5, 2
  • Master of Clinical Oncology, 2010/2011, 8, 532
  • Master of Clinical Oncology, 2009/2010, 10, 532
  • Master of Clinical Oncology, 2008/2009, 7, 309
  • Master of Clinical Oncology, 2007/2008, 7, 309
  • Master of Medical Physics, 2006/2007, 6, 2
  • Master of Clinical Oncology, 2006/2007, 8, 315
  • Master of Otorhinolaryngology, 2005/2006, 10, 3
  • Master of Medical Physics, 2005/2006, 2, 2
  • Master of Clinical Oncology, 2005/2006, 7, 244
  • Master of Clinical Oncology, 2004/2005, 5, 525
  • Master of Internal Medicine, 2004/2005, 8, 1
  • Master of Obstetrics & Gynaecology, 2004/2005, 2, 48
  • Master of Medical Physics, 2004/2005, 5, 2
  • Master of Medical Physics, 2003/2004, 5, 5
  • Master of Clinical Oncology, 2003/2004, 3, 364
  • Master of Clinical Oncology, 2002/2003, 3, 368
  • Master of Medical Physics, 2002/2003, 4, 4
  • Master of Medical Physics, 2001/2002, 4, 3
  • Master of Medical Physics, 2000/2001, 3, 3
FIRST DEGREE
  • UMMP, 2018/2019, 8, 6
  • UMMP, 2016/2017, 160, 2
  • UMMP, 2016/2017, 16, 12
  • UMMP, 2015/2016, 160, 2
  • UMMP, 2015/2016, 24, 30
  • UMMP, 2015/2016, 8, 6
  • UMMP, 2014/2015, 8, 8
  • MBBS, 2007/2008, 150, 2
  • Basic degree in Nursing Sciences, 2007/2008, 30, 1
  • Basic degree in Nursing Sciences, 2006/2007, 39, 2
  • MBBS, 2006/2007, 150, 2
  • MBBS, 2005/2006, 150, 2
  • Basic degree in Nursing Sciences, 2004/2005, 40, 2
  • MBBS, 2004/2005, 160, 2
  • MBBS, 2003/2004, 231, 2
  • basic degree in nursing sciences, 2003/2004, 40, 3
  • MBBS, 2002/2003, 215, 2
  • Basec degree in nursing sciences, 2002/2003, 40, 2
  • MBBS, 2001/2002, 163, 2
  • basic degree in nursing sciences, 2001/2002, 40, 3
  • MBBS, 2000/2001, 153, 2
  • Basic degree in nursing sciences, 2000/2001, 40, 2
DIPLOMA (IF APPLICABLE)
  • Diploma in Radiography, 2004/2005, 27, 1
  • Diploma in Radiography, 2004/2005, 27, 1
  • Diploma in Radiography, 2003/2004, 27, 3
  • Diploma in Radiography, 2002/2003, 23, 3
  • Diploma in Radiography, 2001/2002, 24, 3
  • Diploma in Radiography, 2000/2001, 21, 3
OTHERS
  • Advanced Diploma in Nursing (Oncology), 2008/2009, 8, 3
  • Advanced Diploma in Nursing (Oncology), 2006/2007, 9, 3
  • Advanced Diploma in Nursing (Oncology), 2004/2005, 15, 2
  • Advanced Diploma in Nursing (Oncology), 2003/2004, 18, 2
  • Advanced Diploma in Nursing (Oncology), 2002/2003, 18, 2